Hope to see you at LSI USA '25 Medtech Conference, March 17-20! Looking forward to collaborating with industry experts and fellow innovators and investors! Mi-Helper is emerging as a disruptive force, bringing breakthrough technology to one of the most debilitating global health issues. It is time to bring those suffering with migraine relief. Look me up to find out more!
关于我们
Migraine Relief My Way
- 网站
-
https://mihelper.com/
Mi-Helper, Inc.的外部链接
- 所属行业
- 上门医疗
- 规模
- 11-50 人
- 总部
- Baltimore，MD
- 类型
- 私人持股
地点
-
主要
获取路线
US，MD，Baltimore，21230
Mi-Helper, Inc.员工
动态
-
Every day, I am reminded of the significant challenges faced by those living with migraine—an issue that disproportionately affects women, especially during their childbearing years. It is a profound honor to be part of our dedicated team as we strive to change the game by offering a highly effective, accessible, and affordable non-drug solution for migraine relief. Together, we are committed to making a meaningful difference in the lives of millions who struggle with this disabling condition.
-
We express our heartfelt gratitude to our investors for their support in advancing our mission to provide drug-free relief to those suffering from migraines. #MigraineRelief #MigraineTherapy #MedTech #Financing
Why am I elated? Yesterday Mi-Helper, Inc. completed it's final closing of an oversubscribed $10M Series A Financing. Relief is on the way!!
-
-
The Latest News from Mi-Helper
Mi-Helper successfully secured commitments for a a Series A extension, bolstering their total Series A funding to $10M with an additional $1.6M. This milestone comes on the heels of superb results from a recent nationwide randomized controlled trial. Oversubscription will not be allowed, however a waiting list has been formed for future investment opportunities. We are grateful to our existing and new investors supporting us on our journey to provide a drug-free, affordable, effective, and convenient solution to end migraine attacks. #Healthcare #Innovation #MigraineSolution #Migraine #Medicaldevice #medtech
-
-
The Latest News from Mi-Helper
Mi-Helper successfully secured commitments for a a Series A extension, bolstering their total Series A funding to $10M with an additional $1.6M. This milestone comes on the heels of superb results from a recent nationwide randomized controlled trial. Oversubscription will not be allowed, however a waiting list has been formed for future investment opportunities. We are grateful to our existing and new investors supporting us on our journey to provide a drug-free, affordable, effective, and convenient solution to end migraine attacks. #Healthcare #Innovation #MigraineSolution #Migraine #Medicaldevice #medtech
-
-
Shameless use of pets.
This picture has nothing to do with me attending HLTH 2024 in Vegas. But it made you look. I will be there and talking about the phenomenal Mi-Helper drug free home therapy for migraine and much more. Ask me about the limited extension to the oversubscribed Series A Preferred investment opportunity. Hope to see you there!!!
-
-
Please check out these exciting announcements.
Two significant announcements from Mi-Helper, Inc.! 1) Our recent double-blinded, randomized controlled study revealed statistically significant pain freedom within two hours compared to sham. Study subjects, who self-administered the 15-minute therapy at home, remained pain-free at 24 hours. Stay tuned for the full publication of results. 2) Building on these promising findings, Mi-Helper is increasing the Series A Preferred financing by $1.6M. This extension will also qualify for an Opportunity Zone Level Biotech Incentive Tax Credit, offering a $1.2M cash benefit to participating investors. Exciting developments ahead for Mi-Helper! #Healthcare #Biotech #Innovation #medtech
-
-
Good stuff!!!
Mi-Helper has successfully completed a groundbreaking clinical study to address episodic migraine, involving 172 individuals nationwide. This innovative therapy offers a simple, safe, and drug-free solution, completed in just 15 minutes from the comfort of one's home. Stay tuned for study results for this promising new therapy. Please note that this product is currently intended for investigational use only. #ClinicalStudy #MigraineTreatment #HealthcareInnovation #medtech
-